Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Schizophrenia Models for Advancing Research and Treatment, Preclinical Research Program, National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic.
Exp Brain Res. 2024 May;242(5):1149-1160. doi: 10.1007/s00221-024-06801-2. Epub 2024 Mar 15.
Hypofunctioning of NMDA receptors, and the resulting shift in the balance between excitation and inhibition, is considered a key process in the pathophysiology of schizophrenia. One important manifestation of this phenomenon is changes in neural oscillations, those above 30 Hz (i.e., gamma-band oscillations), in particular. Although both preclinical and clinical studies observed increased gamma activity following acute administration of NMDA receptor antagonists, the relevance of this phenomenon has been recently questioned given the reduced gamma oscillations typically observed during sensory and cognitive tasks in schizophrenia. However, there is emerging, yet contradictory, evidence for increased spontaneous gamma-band activity (i.e., at rest or under baseline conditions). Here, we use the sub-chronic phencyclidine (PCP) rat model for schizophrenia, which has been argued to model the pathophysiology of schizophrenia more closely than acute NMDA antagonism, to investigate gamma oscillations (30-100 Hz) in the medial prefrontal cortex of anesthetized animals. While baseline gamma oscillations were not affected, oscillations induced by train stimulation of the posterior dorsal CA1 (pdCA1) field of the hippocampus were enhanced in PCP-treated animals (5 mg/kg, twice daily for 7 days, followed by a 7-day washout period). This effect was reversed by pharmacological enhancement of endocannabinoid levels via systemic administration of URB597 (0.3 mg/kg), an inhibitor of the catabolic enzyme of the endocannabinoid anandamide. Intriguingly, the pharmacological blockade of CB receptors by AM251 unmasked a reduced gamma oscillatory activity in PCP-treated animals. The findings are consistent with the observed effects of URB597 and AM251 on behavioral deficits reminiscent of the symptoms of schizophrenia and further validate the potential for cannabinoid-based drugs as a treatment for schizophrenia.
NMDA 受体功能低下,以及由此导致的兴奋与抑制之间的平衡转移,被认为是精神分裂症病理生理学的一个关键过程。这种现象的一个重要表现是神经振荡的变化,特别是那些高于 30 Hz(即伽马波段振荡)的振荡。虽然临床前和临床研究都观察到 NMDA 受体拮抗剂急性给药后伽马活动增加,但鉴于精神分裂症患者在感觉和认知任务期间通常观察到伽马振荡减少,这种现象的相关性最近受到质疑。然而,目前有越来越多但相互矛盾的证据表明,自发性伽马波段活动(即在休息或基线条件下)增加。在这里,我们使用亚慢性苯环己哌啶(PCP)大鼠模型来研究精神分裂症,该模型被认为比急性 NMDA 拮抗更能模拟精神分裂症的病理生理学,以研究麻醉动物内侧前额叶皮层的伽马振荡(30-100 Hz)。虽然基线伽马振荡没有受到影响,但在 PCP 处理的动物中,由海马后背部 CA1(pdCA1)场的串刺激诱导的振荡增强(5 mg/kg,每天两次,共 7 天,然后是 7 天的洗脱期)。这一效应通过全身给予 URB597(0.3 mg/kg)来增强内源性大麻素水平而逆转,URB597 是内源性大麻素大麻素酰胺的代谢酶的抑制剂。有趣的是,AM251 对 CB 受体的药理学阻断揭示了 PCP 处理动物的伽马振荡活动减少。这些发现与 URB597 和 AM251 对类似于精神分裂症症状的行为缺陷的观察效应一致,并进一步验证了基于大麻素的药物作为精神分裂症治疗方法的潜力。